Market Intelligence Report
Pharma CDMO Market
Demand Forecast 2020–2030
Global Contract Development & Manufacturing market analysis across Small Molecules, Biologics, and Cell/Gene Therapy — with regional breakdowns across Asia-Pacific, North America, Europe & LAMEA.
$211B
Total market 2026
est. market size
$277B
Total market 2030
7.2% CAGR forecast
42%
Asia-Pacific share
dominant region
24.6%
CGT CAGR
fastest segment
Segment growth outlook
2026 → 2030Small molecules
7.0%
Backbone of CDMO revenue — oral solid-dose pipeline sustains steady growth through outsourcing expansion.
$76.1B → $102.3B
Biologics
7.2%
Monoclonal antibodies, vaccines & complex injectables driving near-doubling of revenue in 4 years.
$76.5B → $153B
Cell & gene therapy
24.6%
Fastest-growing segment — exponential growth driven by advanced therapy pipelines and regulatory momentum.
$8.85B → $21.35B
Fastest
Product segment mix
2026 vs 20302026 — product mix
Total market: $211 billion
Small molecules 63.7%
Biologics 36.3%
Cell/gene 4.2%
2030 — product mix forecast
Total market: ~$277 billion
Small molecules $176B
Biologics $80B
Cell/gene $21B
Total market growth trajectory — 2020 to 2030
USD billions — shaded bars indicate forecast period (2027–2030)
Small molecules
Biologics
Cell & gene therapy
Regional breakdown
2026 actuals & 2030 forecastRegional market share — 2026
Total: $211B
Regional forecast — 2030
Total: ~$277B
Regional product split — 2026 (USD billions)
Small molecules, biologics and cell/gene by region
Small molecules
Biologics
Cell & gene
Regional product split — 2030 forecast (USD billions)
Projected growth across all regions and product categories
Small molecules
Biologics
Cell & gene
Regional summary table
2026 vs 2030| Region | Share % | Small molecules 2026 | Biologics 2026 | Cell/gene 2026 | Total 2026 | Total 2030 | Segment |
|---|---|---|---|---|---|---|---|
| Asia-Pacific | 42% | $56.5B | $32.1B | $3.7B | $88.6B | $116B | Dominant |
| North America | 30% | $38B | $25.3B | $2.5B | $63.3B | $83B | Growth hub |
| Europe | 15% | $19B | $12.4B | $1.5B | $31.7B | $42B | Established |
| LAMEA | 13% | $21B | $6.7B | $1.15B | $27.4B | $36B | Emerging |
Key market insights
AnalysisSmall molecules dominance
Small molecules remain the backbone of CDMO revenue at 63.7% ($134.5B in 2026). The large, established pipeline of oral solid-dose drugs and a strong preference for outsourcing non-core manufacturing activities will sustain this position through 2030, reaching ~$102.3B at a steady 7% CAGR.
Biologics closing the gap
Biologics are nearly doubling from $76.5B to ~$153B by 2030. Monoclonal antibodies, vaccines, and complex injectables are the primary growth engines. Increased manufacturing complexity is accelerating outsourcing to specialized CDMO partners.
Cell & gene — the disruptor
The standout segment — CGT grows at a remarkable 24.6% CAGR, from $8.85B in 2026 to $21.35B by 2030. Advanced therapy pipelines, favourable regulatory momentum, and the extreme manufacturing complexity of CGT products are fuelling explosive demand for specialist CDMOs.
Asia-Pacific's sustained lead
Asia-Pacific holds ~42% of global CDMO revenue ($88.6B in 2026 → $116B in 2030), led by India and China's cost & scale advantages. Growing healthcare infrastructure, lower manufacturing costs, and less stringent regulatory frameworks continue to attract significant outsourcing volume from Western pharma companies.
